Form 8-K

ZIOPHARM ONCOLOGY, INC.

/s/ Robert Hadfield

Date: July 27, 2018

Robert Hadfield

General Counsel and Secretary

0001193125-18-228700.txt : 20180727 0001193125-18-228700.hdr.sgml : 20180727 20180727073058 ACCESSION NUMBER: 0001193125-18-228700 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180723 ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 ITEM INFORMATION: Other Events FILED AS OF DATE: 20180727 DATE AS OF CHANGE: 20180727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZIOPHARM ONCOLOGY INC CENTRAL INDEX KEY: 0001107421 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841475642 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33038 FILM NUMBER: 18973251 BUSINESS ADDRESS: STREET 1: ONE FIRST AVENUE STREET 2: PARRIS BUILDING 34, NAVY YARD PLAZA CITY: BOSTON STATE: MA ZIP: 02129 BUSINESS PHONE: 617-259-1970 MAIL ADDRESS: STREET 1: ONE FIRST AVENUE STREET 2: PARRIS BUILDING 34, NAVY YARD PLAZA CITY: BOSTON STATE: MA ZIP: 02129 FORMER COMPANY: FORMER CONFORMED NAME: EASYWEB INC DATE OF NAME CHANGE: 20010213 8-K 1 d585676d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 23, 2018

ZIOPHARM Oncology, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware	001-33038	84-1475642
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One First Avenue, Parris Building 34, Navy Yard Plaza Boston, Massachusetts		02129
(Address of Principal Executive Offices)		(Zip Code)

(617) 259-1970

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.08

Shareholder Director Nominations.

On July 23, 2018, Ziopharm Oncology, Inc., or the Company, changed the date of the Company’s 2018 Annual Meeting of Stockholders, or the Annual Meeting, from September 19, 2018 (as previously announced) to September 18, 2018. The record date for the Annual Meeting, previously announced as July 23, 2018, and the deadline for qualified stockholder proposals to be presented at the Annual Meeting and included in the Company’s proxy statement and form of proxy, previously announced as July 20, 2018, have not changed. The Annual Meeting will be held at 10:00 a.m. Eastern time at the offices of Cooley LLP located at 1114 Avenue of the Americas, 46th Floor, New York, NY 10036-7798.

Item 8.01

Other Events.

The disclosure in Item 5.08 is incorporated herein by reference thereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.